Pibrentasvir (ABT-530)

Catalog No.S9641 Batch:S964101

Print

Technical Data

Formula

C57H65F5N10O8
Molecular Weight 1113.18 CAS No. 1353900-92-1
Solubility (25°C)* In vitro DMSO 100 mg/mL (89.83 mM)
Ethanol 100 mg/mL (89.83 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50 ranging from 1.4 pM to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.
Targets
GT5a [1]
(Cell-free assay)		 GT1a H77 [1]
(Cell-free assay)		 GT2b [1]
(Cell-free assay)		 GT4a [1]
(Cell-free assay)		 GT3a [1]
(Cell-free assay)		 View More
1.4 pM(EC50) 1.8 pM(EC50) 1.9 pM(EC50) 1.9 pM(EC50) 2.1 pM(EC50)
In vitro

Pibrentasvir is a next-generation HCV NS5A inhibitor with potent and pan-genotypic activity, and it maintains activity against common amino acid substitutions of HCV genotypes 1 to 6 that are known to confer resistance to currently approved NS5A inhibitors.[1]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    Huh-7 human hepatoma cell line, CEM-SS cells

  • Concentrations

    --

  • Incubation Time

    6 days

  • Method

    Antiviral activity assays for HIV-1 and HBV are performed at Southern Research Institute. Pibrentasvir is tested in an HIV-1 antiviral cytoprotection assay using CEM-SS cells and the IIIB strain of HIV-1. Briefly, virus and cells are mixed in the presence of pibrentasvir or zidovudine (AZT; positive control) and incubated for 6 days. The titers of the virus are determined beforehand such that the virus-infected control wells exhibited approximately 85% to 95% loss of cell viability due to virus replication. Therefore, antiviral effect or cytoprotection is observed when a compound prevented virus replication. Six days after infection, 20 to 25 μl of MTS reagent is added per well, and the microtiter plates are then incubated for 4 to 6 h to assess cell viability. Plates are read spectrophotometrically at 490/650 nm with a Molecular Devices Vmax or SpectraMax Plus plate reader.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.